Commentary

Recipe to Success: Innovative Drug Delivery Systems

24 September 2021
Innovative drug delivery systems create a new paradigm for pharmaceuticals, enabling more efficient and targeted administration.

Introduction:  

In April 2021, we invited Dr Rene Holm to share his knowledge of how and why innovative drug delivery systems are created and evaluated. Dr Holm is author or co-author of more than 200 original articles in peer-reviewed journals and patents in biopharmaceutics, pre-formulation, formulation, and physical pharmacy and is an honorary professor in physical chemistry at the Department of Science and Environment, University of Roskilde, Denmark. The following article provides a condensed overview of the topics presented at Formulation and Development Europe: Online, be sure to subscribe to our newsletter to receive updates on our latest conferences and webinars.  

Drivers For Innovative Drug Delivery Systems 

It is not a given that big pharma companies are always searching for novel delivery devices. It is much less expensive if new therapeutics can be delivered through existing, proven devices. Three main drivers cause companies to search out new methods of administration.  

Discovery of a New Compound with Special Properties  

It is possible to discover a new compound, for example, a first in class compound against a specific disease, which has unique properties that require the use of a novel form of delivery device. If the compound is strategically viable, pharmaceutical businesses may test several different forms of delivery devices. This is done with the goal of improving efficacy and ease of use. The increasing discovery and usage of biologics and synthetics have been a critical influence on delivery devices over the last few years.  

Patient Centricity & Need  

Companies are constantly striving to meet patients’ needs and make new delivery devices that are easier to administer and less intrusive. One example is long-acting injectables in the treatments of schizophrenic patients. Patients initially had to take tablets every day, which is easy to forget for multiple reasons. Now we have a delivery system, which is injected as little as four times a year. This helps the patients deal with their disease burdens, and not least – they also hereby receive at more effective disease treatment.  

Engagement In New Modalities and Disease Areas  

Innovative drug delivery systems do not always have to be a novel form of delivery for the industry; instead, companies may engage in new modalities and disease areas with no prior experience due to market trends or expansion opportunities. Janssens’ transition into tackling eye diseases required investment into new delivery devices. As for new modalities, oligonucleotides are rapidly gaining popularity which is likely to require new delivery systems.  

How Are Innovative Drug Delivery Systems Tested? Evaluating their effectiveness and convincing the market  

The next stage is testing potential delivery systems, evaluating their effectiveness and convincing the market and regulatory boards of their usefulness. Testing is essential and needs to be completed before companies can even consider fully implementing delivery systems into development. As with any innovation, there is no guarantee of passing the evaluation stage. The development approach and evaluation process must consider costs.  

Delivery Platform Approach: Targeting Multiple Therapeutic Possibilities  

A platform-based approach provides pharmaceutical and biotech others with accelerated development timeframes and reduced risk; however, this comes with caveats. Developing a device platform requires ensuring that it can be used in the maximum possible range of possible therapeutic areas and patient populations. While this is desirable, it comes with challenges due to the need for flexibility for different volumes and dosing frequencies as therapeutic classes and indications may vary. An excellent platform for cancer treatment may be utterly incompatible with an autoimmune drug owing to drug product characteristics, patient desires, treatment routine, and many other factors. This can cause also lead to compatible drugs being delivered with lower efficacy than a bespoke solution.  

Strong Internal Business Case: Going it alone   

If it is strategically viable, for instance, due to the discovery of a new compound or an industry competition, companies may decide to invest in creating a specialized novel device. This requires more financial input and risk, so it is usually only done for compounds or trends with very high potential returns.  

Companies will often collaborate with Contract Researching Organizations (CROs) and Contract Manufacturing Organizations to reduce risk. Their specialized nature and experience reduce the cost of investment and speed of research, manufacturing, and regulatory approval. CROs and CMOs have grown rapidly in recent years, and their success has led to a shift in procedure. Before the prevalence of such companies, many pharmaceutical organizations were much more risk-averse. In many cases companies avoided anything that was not almost guaranteed to succeed.  

Regardless of the approach taken, many new potential devices never make it to market. It is common to realise during the discovery staged that the device is unfeasible. Devices may be unrealistic from an engineering perspective, unviable due to costs or market demand or simply undesirable to potential patients due to side effects, administration method or industry competition.  

Conclusion:  

The path towards innovative novel delivery paths is expensive and time-consuming. Ensuring that existing and new therapeutics can be administered and simplified is vital. It is essential to bolster the research and advancement of innovative technologies and drug delivery systems within the pharmaceutical industry to ensure the sector can keep up with any improvements in formulation and discovery of new modalities.  

Speaker Biographies

Dr. René Holm – Head and Scientific Director, Drug Product Development – Janssen

Dr. René Holm received his pharmaceutical training at the Royal Danish School of Pharmacy, now the school of pharmacy at the University of Copenhagen, Denmark, in 1998 and his PhD in biopharmaceutics from the same institution in 2002. Dr. Holm joined Lundbeck in 2001 and changed to Janssen in 2016. Dr. Holm has worked within pharmaceutical development, formulations for non-clinical testing in drug discovery, physical chemistry and material science covering both small and large molecules and is now responsible for the functional unit ensuring the development of all non-solid formulations for Janssens small molecule value stream.  

Share this article

Share on facebook
Share on twitter
Share on linkedin

You may also be interested in...

Insight Article
In this Insight Article, we delve into the complex intricacies of the Blood-Brain Barrier, explore its challenge for drug delivery, and look at 3 of the most exciting solution technologies.
01 October 2021
Insight Article
Can Inhaled Biologics make a comeback?  
30 September 2021

Share this article

Share on facebook
Share on twitter
Share on linkedin

Join our Formulation & Delivery mailing list

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Formulation & Delivery

Submit your details to receive the monthly newsletter & to be kept up to date about relevant events, monthly discussion groups and portal membership offers. You may opt-out at any time. Please check our Privacy Policy to see how Oxford Global protects and manages your data.